While the FDA has yet to issue a warning for NAION, it is actively monitoring reports of the condition linked to GLP-1 drugs. There was also chatter in 2025 about a possible adver ...

"This is the first GLP-1 receptor agonists study to show significant reduction in the risk of kidney failure…Our study establishes GLP-1 receptor agonists as an important kidney-protective class of ...

—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...

Please provide your email address to receive an email when new articles are posted on . A link was found between GLP-1 receptor agonist use in PAH and significant decreases in mortality, respiratory ...